New Frost & Sullivan research reveals Asia as Preferred Destination for Clinical Trials
![](https://www.corecommunique.com/wp-content/uploads/2017/03/novotech-300x115.png)
Sydney, Aus, Mar 3, 2017 – (ACN Newswire) – Frost & Sullivan today released its latest white paper, ‘Asia: Preferred Destination for Clinical Trials’, with Asia Pacific specialist CRO Novotech. Research from the new white paper revealed Asia is quickly becoming a clinical research powerhouse; facilitated by the availability of vast treatment-naive patient pools, exceptional …